重症肌无力
医学
耐受性
耐火材料(行星科学)
药理学
重症监护医学
不利影响
内科学
生物
天体生物学
作者
Akiyuki Uzawa,Kimiaki Utsugisawa
标识
DOI:10.1080/14712598.2023.2184257
摘要
Recently, treatments for myasthenia gravis (MG) have progressed significantly. Symptoms of some patients with refractory MG are not relieved by conventional therapies, and such patients might benefit from novel biological treatments that are being developed.We review several novel biological therapies for MG, such as complement inhibitors, neonatal Fc receptor inhibitors, anti-B cell drugs, and IL-6 receptor inhibitors. We also report the modes of action, efficacy, safety, and tolerability of these drugs.Several biological therapies have been developed for MG, and these biologics are promising agents for treating refractory MG. Establishing biomarkers and accumulating evidence of therapeutic response is required to provide the most appropriate biological treatment for each patient.
科研通智能强力驱动
Strongly Powered by AbleSci AI